Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players

Title:Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players

Volume: 27 Issue: 27

Author(s): Emir Muzurović*, Zoja Stanković, Zlata Kovačević, Benida Š. Škrijelj and Dimitri P. Mikhailidis

Affiliation:

• Department of Internal Medicine, Endocrinology section, Clinical Center of Montenegro, Ljubljanska bb, 81000 Podgorica,Montenegro

Keywords: Diabetes mellitus, inflammatory markers, insulin resistance, obesity, atherosclerosis, emerging biomarkers.

Abstract: Diabetes mellitus (DM) is a chronic and complex metabolic disorder, and also an important cause of cardiovascular (CV) diseases (CVDs). Subclinical inflammation, observed in patients with type 2 DM (T2DM), cannot be considered the sole or primary cause of T2DM in the absence of classical risk factors, but it represents an important mechanism that serves as a bridge between primary causes of T2DM and its manifestation. Progress has been made in the identification of effective strategies to prevent or delay the onset of T2DM. It is important to identify those at increased risk for DM by using specific biomarkers. Inflammatory markers correlate with insulin resistance (IR) and glycoregulation in patients with DM. Also, several inflammatory markers have been shown to be useful in assessing the risk of developing DM and its complications. However, the intertwining of pathophysiological processes and the not-quite-specificity of inflammatory markers for certain clinical entities limits their practical use. In this review we consider the advantages and disadvantages of various inflammatory biomarkers of DM that have been investigated to date as well as possible future directions. Key features of such biomarkers should be high specificity, non-invasiveness and cost-effectiveness.

Cite this article as:

Muzurović Emir *, Stanković Zoja , Kovačević Zlata , Škrijelj Š. Benida and Mikhailidis P. Dimitri , Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players, Current Pharmaceutical Design 2021; 27 (27) . https://dx.doi.org/10.2174/1381612826666201125103047